Ultragenyx disclosed that GTX-102 failed to demonstrate benefit versus sham in a large Phase 3 trial of Angelman syndrome, dealing a blow to a rare-disease program that had produced strong early results. The company said the treatment did not improve outcomes compared with controls, according to topline reporting. The result matters for Ultragenyx’s near- to mid-term pipeline and investor expectations, since its commercial footprint is heavily weighted toward ultra-rare therapies and the Angelman asset was widely viewed as a potential path toward broader profitability. The company now faces the need to reassess development plans for GTX-102 and reallocate resources across its neuroscience and rare disease portfolio.